Skip to main content

Advertisement

Log in

Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

An Erratum to this article was published on 23 May 2017

Abstract

Controversies exist about the definition and epidemiology of breakthrough cancer pain (BTcP), the pharmacological treatment options, drug dosing, and how to select the medications for BTcP among the new fentanyl products. Existing data were critically evaluated to provide recommendations by an expert group. An algorithm to diagnose BTcP should be used followed by a careful assessment. Fentanyl products provide efficacy and rapidity of action to counteract the temporal pattern of BTcP. The doses of opioids used for background pain should guide the choice of the doses of fentanyl products. The choice of fentanyl products should be based on individual clinical conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–281

    Article  CAS  PubMed  Google Scholar 

  2. Portenoy RK et al (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134

    Article  CAS  PubMed  Google Scholar 

  3. Mercadante S et al (2015) Italian Oncologic Pain Survey (IOPS): a multi-centre Italian study of breakthrough pain performed in different settings. Clin J Pain 31:214–221

    Article  PubMed  Google Scholar 

  4. Caraceni A et al (2004) Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177–183

    Article  PubMed  Google Scholar 

  5. Mercadante S et al (2009) Breakthrough pain advanced cancer patients : a longitudinal study. Support Care Cancer 38:554–560

    Google Scholar 

  6. Mercadante S et al (2010) Breakthrough pain in oncology : a longitudinal study. J Pain Symptom Manag 40:183–190

    Article  Google Scholar 

  7. Mercadante S et al (2013) Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin 29:93–97

    Article  CAS  PubMed  Google Scholar 

  8. Mercadante S et al (2013) Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Curr Med Res Opin 29:667–671

    Article  PubMed  Google Scholar 

  9. Caraceni A et al (2012) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manag 43:833–841

    Article  Google Scholar 

  10. Greco MT et al (2011) Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the Cancer Pain Outcome Research Study Group. Clin J Pain 27:9–18

    Article  PubMed  Google Scholar 

  11. Gómez-Batiste X et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 24:45–52

    Article  Google Scholar 

  12. Zeppetella G et al (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 20:87–92

    Article  CAS  Google Scholar 

  13. Svendsen KB et al (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9:195–206

    Article  PubMed  Google Scholar 

  14. Swanwick M (2001) The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med 15:9–18

    Article  CAS  PubMed  Google Scholar 

  15. Petzke F, Radbruch L, Zech D, Loick G, Grond S et al (1999) Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manag 17:391–401

    Article  CAS  Google Scholar 

  16. Davies A et al (2011) Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15:756–763

    Article  PubMed  Google Scholar 

  17. Bennett D et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2—management. Pharm Ther 30:354–361

    Google Scholar 

  18. Hagen NA et al (2008) The Alberta Breakthrough pain assessment tool for cancer patients. A validation study using a Delphi process and patient think-alounr interview. J Pain Symptom Manag 35:136–152

    Article  Google Scholar 

  19. Davies A et al (2013) Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag 46:619–628

    Article  Google Scholar 

  20. Mercadante S et al (2014) Breakthrough pain in patients with abdominal cancer pain. Clin J Pain 30:510–514

    Article  PubMed  Google Scholar 

  21. Haugen D et al (2010) Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain 149:476–482

    Article  PubMed  Google Scholar 

  22. Hagen NA et al (2007) A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 10:47–55

    Article  PubMed  Google Scholar 

  23. Webber K et al (2014) Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manag 48:619

    Article  Google Scholar 

  24. Mercadante S et al (2004) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manag 28:505–510

    Article  CAS  Google Scholar 

  25. Hanks GW et al (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zeppetella G (2013) Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Cancer Netw 11:S37–S43

    Article  CAS  Google Scholar 

  27. Mercadante S (2012) Pharmacotherapy for breakthrough cancer pain. Drugs 72:181–190

    Article  CAS  PubMed  Google Scholar 

  28. Jandhyala R et al (2013) Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag 46:573–580

    Article  Google Scholar 

  29. Zeppetella G, Davies AN (2013) Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 10:CD004311. doi:10.1002/14651858.CD004311.pub3

    Google Scholar 

  30. Bedard G et al (2013) A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer 21:2557–2563

    Article  PubMed  Google Scholar 

  31. Davies AN et al (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338

    Article  PubMed  Google Scholar 

  32. Mercadante S (2009) Breakthrough pain: on the road again. Eur J Pain 13:329–430

    Article  PubMed  Google Scholar 

  33. Mercadante S (2011) The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 80:460–465

    Article  PubMed  Google Scholar 

  34. Mercadante S (2011) Rapid onset opioids for breakthrough pain: titrating or not titrating, this is the question. Eur J Pain (Suppl. 2): 443-448

  35. Zeppetella GB (2008) Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manag 35:563–567

    Article  Google Scholar 

  36. Webber K et al (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer. Support Care Cancer 19:2041–2046

    Article  PubMed  Google Scholar 

  37. Mercadante S et al (2013) The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin 29:1527–1532

    Article  CAS  PubMed  Google Scholar 

  38. Mercadante S et al (2013) The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer 21:2335–2339

    Article  PubMed  Google Scholar 

  39. Mercadante S et al (2007) Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 96:1828–1833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mercadante S (2006) Fentanyl buccal tablet in breakthrough pain in opioid-tolerant patients with cancer. Drugs 66:2394–2395

    Article  Google Scholar 

  41. Mercadante S et al (2012) Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 28:963–968

    Article  CAS  PubMed  Google Scholar 

  42. England R et al (2011) How practical are transmucosal fentanyl products for breakthrough cancer pain? A survey of user opinion. BMJ Support Palliat Care 1:349–351

    Article  PubMed  Google Scholar 

  43. Mercadante S et al (2014) Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. J Pain 15:602–607

    Article  CAS  PubMed  Google Scholar 

  44. Mercadante S et al (2014) Patients’ acceptability of different fentanyl products for breakthrough cancer pain. Clin Oncol 26:806

    Article  CAS  Google Scholar 

Download references

Conflict of interest

IOPS activity is sponsored by an unrestricted grant of Molteni Pharmaceutical, Italy.

The authors had full control of all primary data and agree to allow the journal to review their data if requested.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Sebastiano Mercadante.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00520-017-3739-z.

Appendix

Appendix

The IOPS MS Study Group

Mediati Rocco Domenico6, Caruselli Amanda1,Costanzi Andrea2, Russo Gennaro3, Bracchi Paola4, Dodaro Lucia5, Contu Viviana8, Fora Gianluca8, Veronese Barbara10, Alu Massimiliano11, Chiurazzi Bruno12, Sgarlata Massimiliano13, Kasa Alma14, Donelli Emanuela15, Silvestro Stefania15, Romano Carmela17, Ghidoni Silvia18, Palermo Loredana19, Pisanu Giovanni Maria 20, Imperatori Luca21, Diacciati Sara22, Samolsky Dekel Boaz23, Bruno Emanuela24, Saulle Serena25, Bonotto Marta26, De santis Stefano27, Tammaro Dario28, Ginocchi Laura29, Zampieri Mari31, Fioroni Iacopo32, Gallo Gloria33, Saber Benhaz33.

Dauri Mario7, Airoldi Mario8, Azzarello Giuseppe9, Bandera Mauro10, Blasi Livio11, Carteni Giacomo12, Costanzo Veruska13, Degiovanni Daniela14, Fusco Flavio15, Guardamagna Vittorio16, Iaffaioli Vincenzo17, Lazzari Marzia7, Liguori Simeone18, Lorusso Vito19, Mameli Sergio 20, Mattioli Rodolfo21, Mazzei Teresita22, Melotti Rita Maria23, Menardo Valentino24, Miotti Danilo25, Moroso Stefano26, Natoli Silvia7, Orsetti Remo27, Papa Alfonso28, Ricci Sergio29, Sabato Alessandro Fabrizio7, Scelzi Elvira30, Sofia Michele31, Tonini Giuseppe32, Valle Alessandro33

6 Pain Relief, Palliative Care, Oncology Department, Careggi Hospital, Florence Primary Care Unit, ASL RME, Rome,

7 Emergency care, Critical care Medicine, pain Medicine and Anesthesiologydepartement, Tor Vergata University of Rome

8 2nd Medical Oncology Division, Cittàdella Salute e dellaScienza Hospital of Turin, Turin

9 Dip SpecialitàMediche, UOCOncologiaedEmatologiaOncologica; ASL 13 Mirano, Venezia, Italia

10 Ospedaliera Papa Giovanni XXIII - Unit of Paliative Care and Pain Therapy, Bergamo, Italy

11 Medical Oncology Unit, ARNAS Civico, Palermo

12 Medical Oncology, A.O.R.N A. Cardarelli, Naples

13 Palliative Care Unit, SAMO ONLUS, Catania

14 Palliative Care Unit, Ospedale S. Spirito, CasaleMonferrato, Italy

15 SSD Cure Palliative Dipartimento Cure PrimarieedAttivitàDistrettuali ASL3 Genovese

16 UnitàOperativa di Cire Palliative e Terapia del dolore - IRCCS IstitutoEuropeo di Oncologia (IEO) - Milano, Italia

17 Abdominal Medical Oncology, National Cancer Institute, IRCCS Foundation Pascale, Naples

18 Ospedaliera Papa Giovanni XXIII - Unit of Palliative Care and Pain Therapy, Bergamo, Italy

19 Medical Oncology Unit, National Cancer Research Centre "Giovanni Paolo II", Bari

20 Pain Therapy Unit, “A. Businco” Hospital, ASL 8, Cagliari, Italy

21 S. Croce Hospital, Medical Oncology Unit, Fano - Pesaro, Italy

22 Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence

23 Department of Medicine and Surgery Sciences, University of Bologna, Bologna

24 StrutturaSempliceAlgologia, A.O. S. Croce e Carle, Cuneo, Italy

25 Salvatore Maugeri, Foundation IRCCS, Pavia, Italy

26 Medical Oncology, University Hospital S. Maria dellaMisericordia, Udine, Italy

27 Pain Medicine Unit, S. Camillo-Forlanini Hospital, Rome

28 Pain Relief, A.O. Dei Colli, Monaldi Hospital, Naples

29 Division of Medical Oncology, Department of Oncology, S. Chiara University Hospital, Pisa

30 U.O OncologiaMedica, P.O. Castelfranco Veneto- Treviso, Italy

31 U.O.C. Cure Palliative, Hospice e Medicina del Dolore. P.O di GarbagnateM.se, Milano

32 Department of Medical Oncology, Campus Bio-Medico University of Rome

33 Cure Palliative, Fondazione FARO, Torino

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mercadante, S., Marchetti, P., Cuomo, A. et al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer 24, 961–968 (2016). https://doi.org/10.1007/s00520-015-2951-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2951-y

Keywords

Navigation